Claritev Corp Q3 FY2026 earnings call

• Strategic Diversification and Growth: Management emphasized that the horizontal product and vertical market strategy is successfully diversifying revenue sources. Bookings are growing across public sector, provider, and TPA verticals, reducing reliance on the core payer market. Year-to-date bookings exceeded $100 million, with over 50% coming from non-payer markets.
• Innovation and AI Integration: The company showcased new AI-native solutions at its Client Conference, including 'Clara,' an AI agent providing real-time cost insights, and transparency-based pricing tools leveraging MRF data. Dozens of AI agents are now in production, aimed at improving operational efficiency and delivering superior performance compared to industry averages.
• Operational Excellence and Volume Trends: Submitted charges grew 15% year-over-year, reflecting medical inflation and service mix changes. NSA dispute initiations surged 75% year-over-year, with the company claiming 8% better performance than the industry average. Total P-SAVE savings eclipsed $5 billion for the first time in several years.
• Financial Discipline and Cash Flow: Claritev generated $18.1 million in operating cash flow in Q3 and $230.7 million in unlevered free cash flow for the first nine months. The net leverage ratio improved to 7.7 times, and management remains on track to achieve greater than 50% adjusted cash conversion for the full year 2026.

Total revenue for Q3 2026 was $268.3 million, representing a 9.1% year-over-year increase and the highest quarterly revenue in 17 quarters. The company's largest segment, Claims Intelligence, drove this outperformance with 17.1% year-over-year growth, fueled by incremental volumes from a new federal No Surprises Act (NSA) client win. Conversely, the Net Work business declined 5.6% year-over-year, primarily due to the absence of $5.4 million in non-recurring revenue recognized in the prior year. Payment and Revenue Integrity ran slightly behind internal plans, as the transition of clients from legacy clinical negotiations to Claims Intelligence solutions offset the revenue ramp from newer offerings like the Advanced Code Editing (ACE) product. Despite these declines, the company noted that identified potential savings per claim increased over 13% year-over-year, reinforcing value delivery.

• Full-Year 2026 Revenue: Raised to a range of $1.038 billion to $1.043 billion, representing a midpoint increase of $30.5 million from previous guidance. This implies full-year revenue growth of 7.5% to 8%.
• Full-Year 2026 Adjusted EBITDA: Raised to $625 million to $630 million, a midpoint increase of $12.5 million.
• Full-Year 2026 Free Cash Flow: Raised to $10 million to $20 million, up $5 million at the midpoint.
• Capital Expenditures: Tightened guidance to $165 million to $170 million.
• 2027 Preliminary Outlook: Management expects to achieve at least $1.1 billion in revenue in 2027, driven by strong booking momentum and the translation of ACV into revenue. More detailed financial guidance will be provided during the Q4 earnings report in February.

• Regulatory Uncertainty: Management noted that recent rule changes regarding the No Surprises Act (NSA) are still being evaluated, making it difficult to provide long-term outlooks on claims volumes beyond the immediate impact of new customer wins.
• Segment Transition Risks: The decline in Payment and Revenue Integrity highlights the risk associated with transitioning clients from legacy clinical negotiation models to newer Claims Intelligence solutions, which may temporarily suppress segment-level revenue before long-term growth resumes.
• Execution Dependency: The realization of 2027 growth targets relies heavily on the successful conversion of booked ACV into revenue, a process that typically takes two to four quarters for implementation and another four quarters for full annualized contribution.

Q: Analyst asked for segment-level growth drivers and early signs on gross revenue retention vs. organic/ACV contribution.

A: CFO stated Payment & Revenue Integrity is expected to return to growth in 2027. Excluding one-time items, Network business would be up ~5%, while Claims Intelligence performed exceedingly well. Detailed breakdowns are reserved for future guidance.

Q: Analyst questioned CapEx priorities and whether narrowing the range was a pull-forward.

A: CFO clarified that R&D as a % of revenue should normalize from ~16.5% down to ~16% and improve further. The company has one final chunk of investment in its Vision 2030 transformation, expecting strong ROI and operating leverage next year.

Q: Analyst asked why Payment Integrity underperformed and confidence in future growth given low revenue conversion.

A: CFO explained that clients moved from legacy clinical negotiations (~1/3 of segment) to Claims Intelligence, impacting the segment disproportionately. However, >$40M ACV was booked in PRI recently, though only ~20% converted to revenue yet, indicating strong future visibility.

Q: Analyst asked if bookings conversion timelines change when expanding outside the payer segment.

A: CFO noted that while Claims Intelligence converts quickly within existing install bases, new network installs (e.g., World Trade Center) take ~3 quarters. The blended assumption remains 2-4 quarters for implementation and 4 quarters for full ramp.

Q: Analyst asked about the durability of Claims Intelligence growth post-new NSA customer and margin implications.

A: CEO argued macro trends (care moving outside hospital walls) sustain out-of-network volumes. CFO highlighted submitted charges up 15% and savings per claim >$1,500. Company is willing to invest in sales/delivery to diversify, aiming for a 'Rule of 70' status with high margins long-term.